251 related articles for article (PubMed ID: 27513584)
1. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB
Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584
[TBL] [Abstract][Full Text] [Related]
2. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
3. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Wheaton MG; Rosenfield D; Foa EB; Simpson HB
J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
[TBL] [Abstract][Full Text] [Related]
4. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
Simpson HB; Gorfinkle KS; Liebowitz MR
J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
[TBL] [Abstract][Full Text] [Related]
5. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.
Foa EB; Simpson HB; Liebowitz MR; Powers MB; Rosenfield D; Cahill SP; Campeas R; Franklin M; Hahn CG; Hembree EA; Huppert JD; Schmidt AB; Vermes D; Williams MT
J Clin Psychiatry; 2013 May; 74(5):464-9. PubMed ID: 23759449
[TBL] [Abstract][Full Text] [Related]
6. Augmenting obsessive-compulsive disorder treatment: from brain to mind.
Ressler KJ; Rothbaum BO
JAMA Psychiatry; 2013 Nov; 70(11):1129-31. PubMed ID: 24026506
[No Abstract] [Full Text] [Related]
7. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
[TBL] [Abstract][Full Text] [Related]
8. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
[TBL] [Abstract][Full Text] [Related]
9. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
11. Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome.
Morinobu S; Yamashita H; Yamawaki S; Tanaka K; Ohkawa M
J Clin Psychiatry; 2002 Sep; 63(9):838-40. PubMed ID: 12363127
[No Abstract] [Full Text] [Related]
12. Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.
Zandberg LJ; Zang Y; McLean CP; Yeh R; Simpson HB; Foa EB
Behav Res Ther; 2015 May; 68():76-81. PubMed ID: 25824533
[TBL] [Abstract][Full Text] [Related]
13. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD.
O'Neill J
Evid Based Ment Health; 2014 May; 17(2):58-9. PubMed ID: 24713316
[No Abstract] [Full Text] [Related]
14. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of cognitive-behavioral therapy addition to pharmacotherapy in resistant obsessive-compulsive disorder: a multicenter study.
Albert U; Aguglia A; Bogetto F; Cieri L; Daniele M; Maina G; Necci R; Parena A; Salvati L; Tundo A
Psychother Psychosom; 2012; 81(6):383-5. PubMed ID: 22964775
[No Abstract] [Full Text] [Related]
16. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
[TBL] [Abstract][Full Text] [Related]
17. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
[TBL] [Abstract][Full Text] [Related]
18. [Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder].
Vloet TD; Simons M; Herpertz-Dahlmann B
Z Kinder Jugendpsychiatr Psychother; 2012 Jan; 40(1):29-39; quiz 39-40. PubMed ID: 22161940
[TBL] [Abstract][Full Text] [Related]
19. Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response.
Salomoni G; Grassi M; Mosini P; Riva P; Cavedini P; Bellodi L
J Clin Psychopharmacol; 2009 Aug; 29(4):343-9. PubMed ID: 19593173
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Brakoulias V; Stockings E
Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
